Renal cancer: molecular mechanisms and newer therapeutic options.
about
Acoustic radiation force impulse elastography in differentiating renal solid masses: a preliminary experience.Stage T1N0M0 renal cell carcinoma: the prognosis in Asian patientsManagement of side effects associated with sunitinib therapy for patients with renal cell carcinoma.Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.Tumor suppressive microRNA‑138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.Occult renal cell carcinoma manifesting with epistaxis in a woman: a case reportA multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECISTLymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma.Metastasis to the parotid region as an initial presentation of renal cell carcinoma: A case report.MicroRNA-214 Reduces Insulin-like Growth Factor-1 (IGF-1) Receptor Expression and Downstream mTORC1 Signaling in Renal Carcinoma Cells.Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs.CCL2 as a potential therapeutic target for clear cell renal cell carcinoma.Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.Epistaxis as the First Manifestation of Silent Renal Cell Carcinoma: A Case Report with Relevant Literature Review.Radiofrequency Ablation-Assisted Zero-Ischemia Robotic Laparoscopic Partial Nephrectomy: Oncologic and Functional Outcomes in 49 Patients.Safety and efficacy of preoperative sorafenib therapy in facilitating cytoreductive surgery in renal cell carcinoma.Isolated omental metastasis of renal cell carcinoma after extraperitoneal open partial nephrectomy: A case report.VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.NDUFA4L2 is associated with clear cell renal cell carcinoma malignancy and is regulated by ELK1.LRSSLMDA: Laplacian Regularized Sparse Subspace Learning for MiRNA-Disease Association prediction.Metastatic Renal Cell Cancer-Systemic Therapy.The effect of information on preferences for treatments of metastatic renal cell carcinoma.Correlation of T Cell Immunoglobulin and ITIM Domain (TIGIT) and Programmed Death 1 (PD-1) with Clinicopathological Characteristics of Renal Cell Carcinoma May Indicate Potential Targets for Treatment
P2860
Q30422309-67204C55-6C9F-491B-AAB4-B332B9048DDAQ33579266-9065BD27-CA40-4827-8892-673122B7D83FQ33916002-887737EF-3C9F-4C27-9FFD-58954216931BQ34029148-C074FC08-F87A-43CC-BF8E-EDD78D3AC69BQ34286271-4D6185C1-B926-4B1D-A406-9279E41041C5Q34633548-38743816-A3AE-4DB6-AC1E-E8D68BBF5090Q35947955-F2202DAD-5686-4836-B800-944A185B40C5Q36015295-B48A30AE-6A30-40AE-88CF-EA1EE8563696Q36532950-AF8A1AF7-CA40-4D87-B97F-102D33BC3D21Q36621580-F5FF6E13-A2C1-46EA-8300-918B737B9329Q37078685-C217FF1A-B372-4AE0-AEFD-E250A5791420Q37137116-36374D42-0BE0-4ED5-9778-9ADAAA7EFEB4Q37373125-E3A27781-086D-4C3E-BF34-DC1F1ABF3FFEQ37983389-5947B391-9029-44C0-BC73-EAB6D0F9380BQ38172644-09067DA1-415E-4C48-B1BD-A59334BE94E4Q38175454-F1490D48-1C24-4F23-8DD5-1BFC9FCD4829Q38816418-59B4449F-C47F-46AF-A236-4E826F67A578Q39043753-40EF100B-F088-4326-8BD1-6F12A7DB848DQ39198075-271FF6E4-4B95-4ED0-8378-420FDF788ECCQ39306313-78872C89-96A2-4FFF-8CCE-C48826504867Q44011303-4FA684AF-A4C2-49C2-A520-571F66E95A40Q47134100-8FF6C1D8-EEFB-4EB7-AA8B-8D91B5E69A12Q47238496-6A0ECA69-4ABD-4359-811C-29B03EE6D35BQ52643815-FF132DE2-9F60-4FB5-91DA-3C882F8BF075Q53136887-76DE125B-BD8A-47BB-B3F8-1816E8AE1EE3Q58796432-6C917387-A102-4ED1-BD05-69DF242E0411
P2860
Renal cancer: molecular mechanisms and newer therapeutic options.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Renal cancer: molecular mechanisms and newer therapeutic options.
@ast
Renal cancer: molecular mechanisms and newer therapeutic options.
@en
Renal cancer: molecular mechanisms and newer therapeutic options.
@nl
type
label
Renal cancer: molecular mechanisms and newer therapeutic options.
@ast
Renal cancer: molecular mechanisms and newer therapeutic options.
@en
Renal cancer: molecular mechanisms and newer therapeutic options.
@nl
prefLabel
Renal cancer: molecular mechanisms and newer therapeutic options.
@ast
Renal cancer: molecular mechanisms and newer therapeutic options.
@en
Renal cancer: molecular mechanisms and newer therapeutic options.
@nl
P2093
P1476
Renal cancer: molecular mechanisms and newer therapeutic options.
@en
P2093
Jaime Merchan
S Ananth Karumanchi
Vikas P Sukhatme
P356
10.1097/00041552-200201000-00006
P577
2002-01-01T00:00:00Z